Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12122927 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAPK1 | |
| SCHEMBL27320006 | 0.80 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL12932253 | 0.78 | TSHR (0.31) | MAPK1 | |
| SCHEMBL28461985 | 0.78 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL3044735 | 0.78 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL10038935 | 0.78 | HRH3 (0.32) | MAPK1 | |
| SCHEMBL5693068 | 0.77 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL10932413 | 0.76 | MAPK1 (0.36) | ALDH1A1MAPK1 | |
| SCHEMBL10717480 | 0.76 | MAPK1 (0.36) | ALDH1A1MAPK1 | |
| SCHEMBL6257222 | 0.76 | ALDH1A1 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | ALDH1A1 132/4885MAPK1 3042/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | ALDH1A1 2082/4885MAPK1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.